SCHOLAR ROCK HOLDING CORPORATION Operating Lease Cost
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Operating Lease Cost of $1.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION operating lease, cost for the quarter ending 2026-06-30 was $1.81M, a 5.43% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, cost for the quarter ending 2026-03-31 was $1.81M, a 5.54% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, cost for the quarter ending 2025-12-31 was $1.71M, a 0.00% change year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, cost for the quarter ending 2025-09-30 was $1.71M, a 0.00% change year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, cost for fiscal 2025 was $6.86M, a 2.11% decline from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, cost for fiscal 2024 was $7.00M, a 15.93% decline from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, cost for fiscal 2023 was $8.33M, a 3.97% decline from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, cost for fiscal 2022 was $8.68M, a 0.38% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.81M 10-Q · filed 2026-08-06 | $3.62M 10-Q · filed 2026-08-06 | $5.33M derived: sum of 3 quarters · filed 2026-08-06 | $7.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.81M 10-Q · filed 2026-05-07 | $3.52M derived: sum of 2 quarters · filed 2026-05-07 | $5.24M derived: sum of 3 quarters · filed 2026-05-07 | $6.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.43M derived: sum of 2 quarters · filed 2026-03-03 | $5.14M derived: sum of 3 quarters · filed 2026-08-06 | $6.86M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.71M 10-Q · filed 2025-11-14 | $3.43M derived: sum of 2 quarters · filed 2026-08-06 | $5.14M 10-Q · filed 2025-11-14 | $6.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.71M 10-Q · filed 2026-08-06 | $3.43M 10-Q · filed 2026-08-06 | $5.14M derived: sum of 3 quarters · filed 2026-08-06 | $6.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.71M 10-Q · filed 2026-05-07 | $3.43M derived: sum of 2 quarters · filed 2026-05-07 | $5.14M derived: sum of 3 quarters · filed 2026-05-07 | $6.89M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.43M derived: sum of 2 quarters · filed 2026-03-03 | $5.18M derived: sum of 3 quarters · filed 2026-03-03 | $7.00M 10-K · filed 2026-03-03 |
| 2024-09-30 | $1.71M 10-Q · filed 2025-11-14 | $3.46M derived: sum of 2 quarters · filed 2025-11-14 | $5.29M 10-Q · filed 2025-11-14 | $7.12M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.75M 10-Q · filed 2025-08-06 | $3.58M 10-Q · filed 2025-08-06 | $5.40M derived: sum of 3 quarters · filed 2025-08-06 | $7.57M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $1.82M 10-Q · filed 2024-05-07 | $3.65M derived: sum of 2 quarters · filed 2024-05-07 | $5.82M derived: sum of 3 quarters · filed 2024-05-07 | $7.99M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $3.99M derived: sum of 2 quarters · filed 2024-03-19 | $6.16M derived: sum of 3 quarters · filed 2024-03-19 | $8.33M 10-K · filed 2024-03-19 |
| 2023-09-30 | $2.17M 10-Q · filed 2023-11-07 | $4.34M derived: sum of 2 quarters · filed 2023-11-07 | $6.51M 10-Q · filed 2023-11-07 | $8.68M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $2.17M 10-Q · filed 2023-08-09 | $4.34M 10-Q · filed 2023-08-09 | $6.51M derived: sum of 3 quarters · filed 2023-08-09 | $8.68M derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | $2.17M 10-Q · filed 2023-05-09 | $4.34M derived: sum of 2 quarters · filed 2023-05-09 | $6.51M derived: sum of 3 quarters · filed 2023-05-09 | $8.68M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $4.34M derived: sum of 2 quarters · filed 2023-03-07 | $6.51M derived: sum of 3 quarters · filed 2023-03-07 | $8.68M 10-K · filed 2023-03-07 |
| 2022-09-30 | $2.17M 10-Q · filed 2022-11-14 | $4.34M derived: sum of 2 quarters · filed 2022-11-14 | $6.51M 10-Q · filed 2022-11-14 | $8.67M derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | $2.17M 10-Q · filed 2022-08-08 | $4.34M 10-Q · filed 2022-08-08 | $6.50M derived: sum of 3 quarters · filed 2022-08-08 | $8.66M derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | $2.16M 10-Q · filed 2022-05-16 | $4.33M derived: sum of 2 quarters · filed 2022-05-16 | $6.49M derived: sum of 3 quarters · filed 2022-05-16 | $8.65M derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $4.33M derived: sum of 2 quarters · filed 2022-03-07 | $6.49M derived: sum of 3 quarters · filed 2022-03-07 | $8.64M 10-K · filed 2022-03-07 |
| 2021-09-30 | $2.16M 10-Q · filed 2021-11-09 | $4.32M derived: sum of 2 quarters · filed 2021-11-09 | $6.47M 10-Q · filed 2021-11-09 | $8.67M derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | $2.16M 10-Q · filed 2021-08-10 | $4.31M 10-Q · filed 2021-08-10 | $6.51M derived: sum of 3 quarters · filed 2021-08-10 | $6.85M derived: sum of 4 quarters · filed 2021-08-10 |
| 2021-03-31 | $2.15M 10-Q · filed 2021-05-13 | $4.35M derived: sum of 2 quarters · filed 2021-05-13 | $4.70M derived: sum of 3 quarters · filed 2021-05-13 | $5.04M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $2.54M derived: sum of 2 quarters · filed 2021-03-09 | $2.89M derived: sum of 3 quarters · filed 2021-03-09 | $3.23M 10-K · filed 2021-03-09 |
| 2020-09-30 | $344.00K 10-Q · filed 2020-11-09 | $688.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.03M 10-Q · filed 2020-11-09 | $1.38M derived: sum of 4 quarters · filed 2020-11-09 |
| 2020-06-30 | $344.00K 10-Q · filed 2020-08-07 | $687.00K 10-Q · filed 2020-08-07 | $1.03M derived: sum of 3 quarters · filed 2020-08-07 | $1.38M derived: sum of 4 quarters · filed 2020-08-07 |
| 2020-03-31 | $344.00K 10-Q · filed 2020-05-07 | $688.00K derived: sum of 2 quarters · filed 2020-05-07 | $1.03M derived: sum of 3 quarters · filed 2020-05-07 | $1.38M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | $344.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $688.00K derived: sum of 2 quarters · filed 2020-03-12 | $1.03M derived: sum of 3 quarters · filed 2020-03-12 | $1.38M 10-K · filed 2020-03-12 |
| 2019-09-30 | $344.00K 10-Q · filed 2019-11-12 | $687.00K derived: sum of 2 quarters · filed 2019-11-12 | $1.03M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $343.00K 10-Q · filed 2019-08-14 | $686.00K 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $343.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |